Abstract
Objective: We report a case of acute interstitial nephritis (AIN) and immune hemolytic anemia (IHA) associated with cefpodoxime therapy.
Case Summary: A patient with a recent history of cefpodoxime proxetil treatment presented with elevated serum creatinine, oliguria, nausea, vomiting, and dyspnea. Evidence of renal failure, abnormal urinalysis, and renal biopsy with inflammatory infiltrate in the interstitium confirmed a diagnosis of AIN. The patient subsequently developed IHA, which was confirmed by peripheral blood smear results and positive Coombs’ test. The patient recovered after dialysis therapy and 2 days of intravenous methylprednisolone (500mg/day) followed by oral prednisolone (60 mg/day), which was rapidly tapered and stopped within 3 weeks.
Conclusions: To our knowledge, cefpodoxime-induced AIN and IHA are unprecedented. Physicians should be aware that drug-induced AIN and hemolysis can be associated with cefpodoxime proxetil.
Keywords: Acute interstitial nephritis, acute kidney injury, adverse reaction, cefpodoxime proxetil, immune hemolytic anemia, early treatment.
Current Drug Safety
Title:Cefpodoxime Proxetil-Related Hemolysis and Acute Interstitial Nephritis
Volume: 8 Issue: 2
Author(s): Hakki Yilmaz, Mukadder Ayse Bilgic, Nuket Bavbek and Ali Akcay
Affiliation:
Keywords: Acute interstitial nephritis, acute kidney injury, adverse reaction, cefpodoxime proxetil, immune hemolytic anemia, early treatment.
Abstract: Objective: We report a case of acute interstitial nephritis (AIN) and immune hemolytic anemia (IHA) associated with cefpodoxime therapy.
Case Summary: A patient with a recent history of cefpodoxime proxetil treatment presented with elevated serum creatinine, oliguria, nausea, vomiting, and dyspnea. Evidence of renal failure, abnormal urinalysis, and renal biopsy with inflammatory infiltrate in the interstitium confirmed a diagnosis of AIN. The patient subsequently developed IHA, which was confirmed by peripheral blood smear results and positive Coombs’ test. The patient recovered after dialysis therapy and 2 days of intravenous methylprednisolone (500mg/day) followed by oral prednisolone (60 mg/day), which was rapidly tapered and stopped within 3 weeks.
Conclusions: To our knowledge, cefpodoxime-induced AIN and IHA are unprecedented. Physicians should be aware that drug-induced AIN and hemolysis can be associated with cefpodoxime proxetil.
Export Options
About this article
Cite this article as:
Yilmaz Hakki, Bilgic Ayse Mukadder, Bavbek Nuket and Akcay Ali, Cefpodoxime Proxetil-Related Hemolysis and Acute Interstitial Nephritis, Current Drug Safety 2013; 8 (2) . https://dx.doi.org/10.2174/15748863113089990028
DOI https://dx.doi.org/10.2174/15748863113089990028 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Connexins in Renal Endothelial Function and Dysfunction
Cardiovascular & Hematological Disorders-Drug Targets Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Editorial:
Current Immunology Reviews (Discontinued) Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Exosomes: A Novel Therapeutic Paradigm for the Treatment of Depression
Current Drug Targets Outcome Prediction after Non-aneurysmal Non-traumatic Subarachnoid Hemorrhage
Current Neurovascular Research Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology Role of Platelets in Angiogenesis in Health and Disease
Current Angiogenesis (Discontinued) Diversity of Human Immune System Multigene Families and its Implication in the Genetic Background of Rheumatic Diseases
Current Medicinal Chemistry Role of Endothelial Progenitor Cell Mobilization After Percutaneous Angioplasty Procedure
Current Pharmaceutical Design A Pulmonary Perspective on GASPIDs: Granule-Associated Serine Peptidases of Immune Defense
Current Respiratory Medicine Reviews Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine
Current Medicinal Chemistry Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease
Current Vascular Pharmacology Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design TRP Channels: Emerging Links Between Ca2+, Kidney and Hypertension
Current Hypertension Reviews The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Review of Pediatric Uveitis
Current Pediatric Reviews Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited
Current Medicinal Chemistry